-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Cm51Mj9RvCYJrq0OnYkFTSW6g1EqcHf3VmQ4yW6B5bjKj3QxN370M/91HTScIKB/ wGc1F29i1Ide4X84m3Xskw== 0000950162-04-000210.txt : 20040217 0000950162-04-000210.hdr.sgml : 20040216 20040217141534 ACCESSION NUMBER: 0000950162-04-000210 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040217 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ELAN PHARMACEUTICAL INVESTMENTS II LTD CENTRAL INDEX KEY: 0001256814 IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: CLAREDON HOUSE STREET 2: CHURCH STREET CITY: HAMILTON BERMUDA STATE: D0 ZIP: 00000 BUSINESS PHONE: 4412929169 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NANOGEN INC CENTRAL INDEX KEY: 0001030339 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 330489621 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-54207 FILM NUMBER: 04607131 BUSINESS ADDRESS: STREET 1: 10398 PACIFIC CENTER COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858 410 4600 MAIL ADDRESS: STREET 1: 10398 PACIFIC CENTER COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 SC 13G 1 nanogensc13g021703.txt SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Nanogen, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $.001 per Share - -------------------------------------------------------------------------------- (Title of Class of Securities) 630075 10 9 - -------------------------------------------------------------------------------- (CUSIP Number) June 29, 2000 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / / Rule 13d-1(b) /X/ Rule 13d-1(c) / / Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). -2- - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Elan Pharmaceutical Investments II, Ltd. - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Bermuda - -------------------------------------------------------------------------------- 5. Sole Voting Power 1,287,878 ----------------------------------------------------- Number of 6. Shared Voting Power Shares Beneficially 0 ----------------------------------------------------- Owned by Each 7. Sole Dispositive Power Reporting Person With: 1,287,878 ----------------------------------------------------- 8. Shared Dispositive Power 0 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,287,878 - -------------------------------------------------------------------------------- 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / / - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 5.3% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) CO -3- Item 1(a). Name of Issuer: Nanogen, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 10398 Pacific Center Court, San Diego, CA 92121 Item 2(a). Name of Person Filing: This statement is filed on behalf of Elan Pharmaceutical Investments II, Ltd. (the "Reporting Person") Item 2(b). Address of Principal Business Office: Elan Pharmaceutical Investments II, Ltd. Clarendon House Church Street Hamilton, Bermuda Item 2(c). Citizenship: Elan Pharmaceutical Investments II, Ltd. is a Bermuda exempted limited liability company Item 2(d). Title of Class of Securities: Common Stock, par value $.001 per share (the "Shares") Item 2(e). CUSIP Number: 630075 10 9 Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a: This Item 3 is not applicable Item 4. Ownership: (a) Amount beneficially owned: 1,287,878 (b) Percent of class: 5.3% (c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 1,287,878 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,287,878 (iv) shared power to dispose or to direct the disposition of: 0
-4- Item 5. Ownership of Five Percent or Less of a Class: Not Applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable Item 8. Identification and Classification of Members of the Group: Not Applicable Item 9. Notice of Dissolution of Group: Not Applicable Item 10. Certifications: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. -5- SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 17, 2004 ELAN PHARMACEUTICAL INVESTMENTS II, LTD. By: /s/ Kevin Insley ---------------------------------- Name: Kevin Insley Title: Vice President -----END PRIVACY-ENHANCED MESSAGE-----